InMode Ltd.
HealthcareNASDAQ:INMD · NASDAQ Global Select
-$0.04 today
Vol 0.43M · Avg 0.91M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
13.7%
avg 29.9%
ROIC
10.4%
avg 25.2%
ROA
12.2%
avg 22.3%
Analysis
ROE is currently the strongest return metric at 13.7% versus its period average of 29.9%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Dennison | President of North America | $1.79M | — | 45 | $9,000.00 | 0.01% |
Brandon Nye | Vice President of Sales of West US | $1.66M | — | — | — | — |
Moshik Itzkovich | Chief Financial Officer | $763,000.00 | — | — | $6,430.00 | 0.01% |
Yair Malca | Consultant | $763,000.00 | — | 48 | $94,192.00 | 0.15% |
Matt Rodgers | Vice President of Sales of Canada | $678,000.00 | — | — | — | — |
Michael Kreindel | Co-Founder, Chief Technology Officer & Director | $267,000.00 | — | 58 | $9,000.00 | 0.01% |
Nava Tal-Launer | Chief Information Officer | $229,000.00 | — | — | — | — |
Moshe Mizrahy | Co-Founder, Chief Executive Officer & Director | $216,000.00 | — | 73 | $6,430.00 | 0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +85.2% | +6.8% (8yr)4 analysts |
| Revenue | N/A | N/A | +56.8% | +8.3% (8yr)4 analysts |
| Net Income | N/A | N/A | +104.1% | +3.7% (8yr)4 analysts |
| EBIT | N/A | N/A | +101.1% | +9.1% (8yr)4 analysts |
Analysis
Recent growth has been strongest in Net Income at +104.1% over three years. Forward estimates point to EBIT at +9.1% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.42B
AxoGen, Inc.
NASDAQ:AXGN
$2.29B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
IRadimed Corporation
NASDAQ:IRMD
$1.20B
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
$1.14B
OPKO Health, Inc.
NASDAQ:OPK
$1.07B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Oculis Holding AG
NASDAQ:OCS
$634.01M
Claritev Corporation
NYSE:CTEV
$526.61M
Who manages INMD?
InMode Ltd. (INMD) lists 8 active executives. The top listed executive is Brandon Nye, Vice President of Sales of West US.
Are INMD insiders buying or selling?
Recent insider activity shows net buying of $18.83M.
Explore More
Continue the stock analysis
Jump to another research area for this company.